Clinical trial
A Double-Blind, Placebo-Controlled Study of the Probiotic Ganeden BC30 (Bacillus Coagulans GBI-30, 6068) in Irritable Bowel Syndrome Comorbid With Major Depressive Disorder (MDD)
NCT01337609 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled Study of the Probiotic Ganeden BC30 (Bacillus Coagulans GBI-30, 6068) in Irritable Bowel Syndrome Comorbid With Major Depressive Disorder (MDD)
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- June 30, 2011
- Completion date
- February 29, 2012
- Enrollment
- 5 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.